Press
releases

Oct 14, 2023

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Read more
Oct 12, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
Oct 09, 2023

Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

Read more
Oct 05, 2023

Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023

Read more
Sep 20, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
Aug 31, 2023

Ultragenyx to Participate at Investor Conferences in September

Read more
Aug 18, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
Aug 03, 2023

Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update

Read more
Jul 31, 2023

Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Read more
Jul 27, 2023

Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update

Read more
Sign up for Email Alerts
Email Alerts Sign-up